| Assessment Status |
Awaiting full HTA submission from Applicant |
| HTA ID |
26023 |
| Drug |
Rozanolixizumab |
| Brand |
Rystiggo® |
| Indication |
Rozanolixizumab (Rystiggo®) is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. |
| Rapid review commissioned |
13/05/2026 |
| Rapid review completed |
28/05/2026 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of rozanolixizumab compared with the current standard of care. |
| Full HTA commissioned by the HSE |
19/06/2026 |
| Pre-submission consultation with Applicant |
26/08/2026 |
